Anxiety · people with inflammatory bowel disease
2 findings from 1 review
Depression at 12 weeks · people with inflammatory bowel disease
1 finding from 1 review
Depression at 12 months · people with inflammatory bowel disease
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Pain · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of remission · people with inflammatory bowel disease
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
1 finding from 1 review
Endoscopic relapse · people with inflammatory bowel disease
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
1 finding from 1 review
Depression severity: final score (interviewer‐rated scales) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Response to antidepressive treatment · people with co‐occurring depression and alcohol dependence
It is very uncertain whether antidepressants changes response to antidepressive treatment compared with placebo: all studies (very low certainty).
1 finding from 1 review
Percent of days abstinent · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Consumption of alcohol: abstinent participants (number) · people with co‐occurring depression and alcohol dependence
Antidepressants probably leads to higher consumption of alcohol: abstinent participants (number) compared with placebo: all studies (moderate certainty).
1 finding from 1 review
Amount of alcohol consumed, short term (3‐6 months) measured using the number of drinks/drinking day (in past week to 30 days) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Acceptability ‐ total dropouts · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in acceptability: dropouts compared with placebo: all studies (low certainty).
1 finding from 1 review
Tolerability of treatment: withdrawal for medical reasons · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in tolerability of treatment: withdrawal for medical reasons compared with placebo: all studies (low certainty).
1 finding from 1 review
Dropout ‐ Dropouts: excluding studies with high risk of bias objective · patients with cocaine abuse and dependence
Antidepressants showed no clear difference in dropout ‐ Dropouts: excluding studies with high risk of bias objective compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Abstinence · patients with cocaine abuse and dependence
Antidepressants showed no clear difference in abstinence, for at least three consecutive weeks objective compared with placebo according to any definition (high certainty).
1 finding from 1 review
Number withdrawn due to adverse events · patients with cocaine abuse and dependence
Antidepressants showed no clear difference in adverse events ‐ Withdrawn due to adverse events compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ All studies objective compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review